DBV Technologies

189 articles with DBV Technologies

• DBV Tech, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin Rpt For Booster Vaccination Against Pertussis

  11/17/2016

• DBV Tech Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients

  11/8/2016

• There's A Patch That Could Fix Your Peanut Allergy Problem, DBV Tech Reveals

  11/2/2016

• DBV Tech Announces Publication Of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study In The Journal Of Allergy And Clinical Immunology

  10/27/2016

• The First Peanut Allergy Therapy Might Soon Hit The Shelves, DBV Tech Reveals

  10/26/2016

• DBV Tech Release: Topline Results From Two-Year Follow-Up Study Of Viaskin Peanut Show Long-Lasting And High Levels Of Desensitization To Peanut

  10/25/2016

• DBV Tech Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow’s Milk Protein Allergy

  9/21/2016

• DBV Tech Release: Late-Breaking Presentation At EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights For Monitoring Treatment Progression

  6/16/2016

• DBV Tech Announces Publication Of Preclinical Data In JACI Suggesting EPIT Provides Sustained Protection Against Anaphylaxis

  6/13/2016

• DBV Tech Announces Appointment Of Leading Japanese Allergist, Dr. Motohiro Ebisawa, To Its Scientific Advisory Board

  6/8/2016

• DBV Tech Data At EAACI 2016 Highlight Its Expansive Product Development In Food Allergies

  6/1/2016

• DBV Tech And Nestlé Health Science Form Collaboration To Develop And Commercialize A Novel Diagnostic Test For Pediatric Milk Allergy

  5/31/2016

• DBV Tech Announces Filing Of 2015 "Document de Référence" And 2015 Annual Report On Form 20-F

  4/29/2016

• DBV Tech To Attend Upcoming Investor Conferences

  4/28/2016

• DBV Tech Announces Publication Of Experimental Data On Targeted Regulatory T Cell Induction During Epicutaneous Immunotherapy

  4/12/2016

• DBV Tech Reports Full Year 2015 Financial Results

  4/7/2016

• DBV Tech Release: Additional Phase IIb Trial Results With Viaskin Peanut Presented At The 2016 AAAAI Meeting Continue To Support Treatment Safety, Efficacy And Compliance

  3/7/2016

• DBV Tech Announces Presentation From National Institute of Allergy And Infectious Diseases (NIAID)-Sponsored CoFAR6 Phase II Trial Reaffirming Viaskin Peanut Safety And Efficacy

  3/7/2016

• DBV Tech Announces Publication Of Phase Ib Trial Results In The Journal Of Allergy And Clinical Immunology (JACI) Supporting Safety And Tolerability Of Viaskin Peanut

  2/26/2016

• DBV Tech To Present New Data At The 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting

  2/10/2016